AAM: Drug Negotiations Inadvertently Favor Brand Biologics

By Maaisha Osman / April 9, 2025 at 3:22 PM

The Medicare drug price negotiation program may inadvertently favor expensive brand-name biologics over cheaper biosimilars, Craig Burton, executive director of the Biosimilars Council at the Association for Accessible Medicines, told House lawmakers Tuesday (April 8).


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.